BL
MCID: BRK010
MIFTS: 69

Burkitt Lymphoma (BL) malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Burkitt Lymphoma

Aliases & Descriptions for Burkitt Lymphoma:

Name: Burkitt Lymphoma 54 12 50 24 56 66 13 52 42 14 38 69
Burkitt's Lymphoma 38 12 50 29 14
Bl 50 24 66
Small Non-Cleaved Cell Lymphoma, Burkitt's Type 12
Malignant Lymphoma, Burkitt's Type 12
Small Non-Cleaved Cell Lymphoma 56
Lymphoma, Small Noncleaved-Cell 69
Burkitt's Tumor or Lymphoma 12
Burkitt Lymphoma/leukaemia 12
Burkitt's Tumor 12
Burkitt Tumor 66

Characteristics:

Orphanet epidemiological data:

56
burkitt lymphoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-5/10000 (Africa),1-9/1000000 (United States); Age of onset: All ages; Age of death: any age;

HPO:

32
burkitt lymphoma:
Inheritance sporadic


Classifications:



External Ids:

OMIM 54 113970
Disease Ontology 12 DOID:8584
ICD10 33 C83.7 C83.70
ICD9CM 35 200.2
MeSH 42 D002051
NCIt 47 C2912 C7400
Orphanet 56 ORPHA543
UMLS via Orphanet 70 C0006413 C0079770
ICD10 via Orphanet 34 C83.7
MESH via Orphanet 43 D002051 D008228
MedGen 40 C0006413
UMLS 69 C0006413

Summaries for Burkitt Lymphoma

NIH Rare Diseases : 50 burkitt lymphoma (bl) is a rare, aggressive form of b-cell non-hodgkin's lymphoma, a type of cancer that affects the organs of the immune system. it is more common in males than females. three forms exist: one endemic to africa that is linked to the epstein barr virus (ebv); a sporadic form that develops mainly in the abdomen; and an immunodeficiency-associated form that occurs most commonly in individuals with hiv infection. bl can also develop in the ear, nose, throat and more rarely in other locations. signs and symptoms may differ depending on the form of bl and the organs or body systems affected. the exact cause of the condition is not known. treatment typically includes a few months of intensive chemotherapy; the current cure rate is estimated to be about 80-90%. last updated: 6/26/2012

MalaCards based summary : Burkitt Lymphoma, also known as burkitt's lymphoma, is related to small non-cleaved cell lymphoma and leukemia, acute lymphoblastic 3, and has symptoms including abdominal pain, nausea and vomiting and hyperuricemia. An important gene associated with Burkitt Lymphoma is MYC (MYC Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are Akt Signaling and Allograft rejection. The drugs Bexxar and Erivedge have been mentioned in the context of this disorder. Affiliated tissues include Blood and Blood, and related phenotypes are hematopoietic system and endocrine/exocrine gland

Disease Ontology : 12 A mature B-cell neoplasm of B-cells found in the germinal center.

OMIM : 54 Burkitt lymphoma is a rare, aggressive B-cell lymphoma that accounts for 30 to 50% of lymphomas in children but only 1... (113970) more...

UniProtKB/Swiss-Prot : 66 Burkitt lymphoma: A form of undifferentiated malignant lymphoma commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass.

Related Diseases for Burkitt Lymphoma

Diseases related to Burkitt Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 107)
id Related Disease Score Top Affiliating Genes
1 small non-cleaved cell lymphoma 12.4
2 leukemia, acute lymphoblastic 3 11.0
3 bare lymphocyte syndrome, type ii, complementation group c 11.0
4 bare lymphocyte syndrome, type i 11.0
5 childhood ovarian cancer 11.0
6 blind loop syndrome 11.0
7 lymphoma 10.8
8 prader-willi syndrome due to translocation 10.3 BCL6 CXCR5
9 b-cell lymphomas 10.3
10 diffuse large b-cell lymphoma 10.2
11 erysipelas 10.2 CD40LG IFNA1
12 hyperparathyroidism, primary, caused by water clear cell hyperplasia 10.2 AICDA CD40 CD40LG
13 bursitis 10.2 AICDA CD40 CD40LG
14 immunoglobulin beta deficiency 10.2 AICDA CD40 CD40LG
15 epileptic encephalopathy, early infantile, 33 10.2 AICDA CD40 CD40LG
16 hypoparathyroidism, x-linked 10.2 AICDA CD40 CD40LG
17 anterior foramen magnum meningioma 10.1 BCL6 CD40LG IFNA1 MYC
18 leukemia 10.1
19 angiosarcoma 10.1 CD40 CD40LG PAX5
20 dermatophytosis 10.1 CD40LG IFNA1
21 ectodermal dysplasia 10.1 BCL6 MYC PAX5
22 temtamy syndrome 10.1 AICDA BCL6 CD40 CD40LG
23 basal ganglia disease 10.1 BCL6 CD40LG CR2 PAX5
24 childhood choriocarcinoma of the testis 10.1 CD40 CD40LG SH2D1A
25 mesothelioma, somatic 10.1 BCL6 CD40 CD40LG CXCL13 CXCR5
26 pancreas disease 10.0 CD40LG CR2 SH2D1A
27 advanced sleep phase syndrome, familial, 1 10.0 CD40 CD40LG CXCL13 IFNA1
28 carnitine-acylcarnitine translocase deficiency 10.0 BCL6 BCL7A MS4A1 PAX5
29 hypogonadotropic hypogonadism 2 with or without anosmia 10.0 CD40LG CR2 SH2D1A
30 lip cancer 10.0 BCL6 CCND3 PAX5
31 brain germinoma 10.0 CD40 CD40LG CR2 SH2D1A
32 lymphoblastic leukemia 10.0
33 tall cell variant papillary carcinoma 9.9 AICDA BCL6 CD40 CD40LG MYC SH2D1A
34 intussusception 9.9
35 malaria 9.9
36 hyperphosphatasia with mental retardation syndrome 2 9.9 DNTT MYC PAX5
37 cutis laxa, autosomal recessive, type ib 9.8 CCND3 CD40 CD40LG IFNA1 MYC
38 extraocular retinoblastoma 9.8 CCND2 CCND3 MYC
39 ileocolitis 9.8
40 hemolytic anemia 9.8
41 plasmodium falciparum malaria 9.8
42 integumentary system benign neoplasm 9.8 CCND2 CCND3 MYC
43 gingival recession 9.8 AICDA BCL6 CD40 CR2 CXCR5 MS4A1
44 congestive heart failure 9.8 AICDA CD40 CD40LG CR2 MS4A1 SH2D1A
45 thrombosis 9.7
46 hepatitis 9.7
47 lymphoblastic lymphoma 9.7
48 carotidynia 9.7
49 pancreatitis 9.7
50 acquired immunodeficiency syndrome 9.7

Graphical network of the top 20 diseases related to Burkitt Lymphoma:



Diseases related to Burkitt Lymphoma

Symptoms & Phenotypes for Burkitt Lymphoma

Symptoms by clinical synopsis from OMIM:

113970

Clinical features from OMIM:

113970

Human phenotypes related to Burkitt Lymphoma:

56 32 (show all 14)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abdominal pain 56 32 Occasional (29-5%) HP:0002027
2 nausea and vomiting 56 32 Occasional (29-5%) HP:0002017
3 hyperuricemia 56 32 Frequent (79-30%) HP:0002149
4 abnormality of the ovary 56 32 Occasional (29-5%) HP:0000137
5 intestinal obstruction 56 32 Occasional (29-5%) HP:0005214
6 abnormality of the pancreas 56 32 Occasional (29-5%) HP:0001732
7 gastrointestinal hemorrhage 56 32 Occasional (29-5%) HP:0002239
8 abnormality of the spleen 56 32 Occasional (29-5%) HP:0001743
9 abnormal lactate dehydrogenase activity 56 32 Frequent (79-30%) HP:0045040
10 abnormality of the liver 56 32 Occasional (29-5%) HP:0001392
11 abnormality of bone marrow cell morphology 56 32 Frequent (79-30%) HP:0005561
12 abnormality of the lymph nodes 56 32 Occasional (29-5%) HP:0002733
13 neoplasm of the oral cavity 56 32 Frequent (79-30%) HP:0100649
14 burkitt lymphoma 32 HP:0030080

MGI Mouse Phenotypes related to Burkitt Lymphoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.19 AICDA BAX BCL6 CCND2 CCND3 CD40
2 endocrine/exocrine gland MP:0005379 9.97 BAX BCL6 CCND2 CCND3 CD40 CD40LG
3 homeostasis/metabolism MP:0005376 9.93 CCND2 CCND3 BAX BCL6 CD40 CD40LG
4 immune system MP:0005387 9.89 CXCL13 CXCR5 DNTT MS4A1 MYBL1 MYC
5 normal MP:0002873 9.28 AICDA BCL6 CCND3 CD40 DNTT MYBL1

Drugs & Therapeutics for Burkitt Lymphoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Bexxar 17 46 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa Approved June 2003
2
Erivedge 17 46 VISMODEGIB Genentech Approved January 2012

Drugs for Burkitt Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 483)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
2
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-02-2 5743
4
Ifosfamide Approved Phase 4,Phase 3,Phase 2,Phase 1 3778-73-2 3690
5
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
6
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1 174722-31-7 10201696
7
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
8
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
9
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
10
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
11
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
12
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
13
Mitoxantrone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 65271-80-9 4212
14
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
15
Thiotepa Approved Phase 4,Phase 2,Phase 3,Phase 1 52-24-4 5453
16
Vindesine Approved Phase 4,Phase 3,Phase 2 59917-39-4, 53643-48-4 40839
17
Asparaginase Approved Phase 4,Phase 3,Phase 2 9015-68-3
18
Daunorubicin Approved Phase 4,Phase 2,Phase 3,Phase 1 20830-81-3 30323
19
Teniposide Approved Phase 4,Phase 2,Phase 1 29767-20-2 34698
20
Thioguanine Approved Phase 4,Phase 3,Phase 2 154-42-7 2723601
21
Tenofovir Approved, Investigational Phase 4 147127-20-6 464205
22
Azathioprine Approved Phase 4 446-86-6 2265
23
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
24
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 54575, 6560146 143
25
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
26 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 BB 1101 Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
30 Dexamethasone 21-phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 Dexamethasone acetate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1177-87-3
32 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Isophosphamide mustard Phase 4,Phase 3,Phase 2,Phase 1
34 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
36 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
39 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
40 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
41 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
46 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
49 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
50 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 704)
id Name Status NCT ID Phase
1 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4
2 Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults Completed NCT00199082 Phase 4
3 German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4
4 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
5 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
6 To Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Recruiting NCT02585947 Phase 4
7 Thiopurine Induced Pancreatitis in IBD Patients Recruiting NCT02281799 Phase 4
8 LMBA02 Protocol for Patients With a Burkitt Lymphoma Unknown status NCT00180882 Phase 3
9 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
10 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
11 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3
12 Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00053768 Phase 3
13 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3
14 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
15 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3
16 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
17 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
18 Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia Completed NCT00381680 Phase 3
19 Treatment of Acute Lymphoblastic Leukemia (ALL) in Younger Adults Completed NCT00327678 Phase 3
20 Positron Emission Tomography Guided Therapy of Aggressive Non-Hodgkin's Lymphomas Completed NCT00554164 Phase 3
21 Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis Completed NCT00838214 Phase 2, Phase 3
22 Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia Completed NCT00005977 Phase 3
23 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
24 Interleukin-2 or Observation Following Radiation Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3
25 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma Completed NCT00003595 Phase 3
26 Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Who Have Undergone Stem Cell Transplantation Completed NCT00031668 Phase 3
27 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3
28 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3
29 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
30 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3
31 Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma Completed NCT00002576 Phase 3
32 Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00278421 Phase 3
33 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed NCT00278408 Phase 3
34 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
35 SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00004031 Phase 3
36 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
37 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
38 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
39 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
40 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
41 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
42 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
43 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3
44 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3
45 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
46 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3
47 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3
48 Comparison of Nutritional Supplements in Preventing Weight Loss in Patients With Cancer Completed NCT00053053 Phase 3
49 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3
50 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3

Search NIH Clinical Center for Burkitt Lymphoma

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Burkitt Lymphoma cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: burkitt lymphoma

Genetic Tests for Burkitt Lymphoma

Genetic tests related to Burkitt Lymphoma:

id Genetic test Affiliating Genes
1 Burkitt Lymphoma 29 24 MYC

Anatomical Context for Burkitt Lymphoma

MalaCards organs/tissues related to Burkitt Lymphoma:

39
B Cells, Bone, Bone Marrow, Liver, Ovary, Lymph Node, Pancreas
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Burkitt Lymphoma:
id Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease

Publications for Burkitt Lymphoma

Articles related to Burkitt Lymphoma:

(show top 50) (show all 273)
id Title Authors Year
1
ZDHHC11 and ZDHHC11B are critical novel components of the oncogenic MYC-miR-150-MYB network in Burkitt lymphoma. ( 28331227 )
2017
2
Primary Burkitt lymphoma of the supraglottic larynx: a case report and review of the literature. ( 28279203 )
2017
3
Comprehensive Transcriptome and Mutational Profiling of Endemic Burkitt Lymphoma Reveals EBV Type-Specific Differences. ( 28465297 )
2017
4
Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report. ( 28474336 )
2017
5
Prognostic Impact of MUM1/IRF4 Expression in Burkitt Lymphoma (BL): A Reappraisal of 88 BL Patients in Japan. ( 28079574 )
2017
6
The effects of DLEU1 gene expression in Burkitt lymphoma (BL): potential mechanism of chemoimmunotherapy resistance in BL. ( 28427156 )
2017
7
Frondoside A induces AIF-associated caspase-independent apoptosis in Burkitt lymphoma cells. ( 28508718 )
2017
8
EBVa89BARTa896a893p and cellular microRNAa89197 compromise the immune defense of host cells in EBVa89positive Burkitt lymphoma. ( 28259992 )
2017
9
Gastroduodenal Burkitt Lymphoma Presenting as Demyelinating Polyneuropathy. ( 28532696 )
2017
10
The role of traditional healers in the diagnosis and management of Burkitt lymphoma in Cameroon: understanding the challenges and moving forward. ( 28399870 )
2017
11
Human and Epstein-Barr Virus miRNA Profiling as Predictive Biomarkers for Endemic Burkitt Lymphoma. ( 28400759 )
2017
12
Efficacy and tolerability of chemotherapy in Chinese patients with AIDS-related Burkitt lymphoma and diffuse large B-cell lymphoma: An observational study. ( 28507339 )
2017
13
Burkitt lymphoma. ( 28508391 )
2017
14
Burkitt Lymphoma in Adult With Atypical Clinical Presentation Primarily Involving the Oral Soft Tissue. ( 28328599 )
2017
15
Unveiling Another Missing Piece in EBV-Driven Lymphomagenesis: EBV-Encoded MicroRNAs Expression in EBER-Negative Burkitt Lymphoma Cases. ( 28298901 )
2017
16
Intestinal Burkitt lymphoma in a patient with coeliac disease. ( 28363349 )
2017
17
Oculomotor nerve palsy as a preceding symptom of adult sporadic Burkitt lymphoma: A case report and review of the literature. ( 28454254 )
2017
18
Immune Hemolytic Anemia (Paroxysmal Cold Hemoglobinuria) Preceding Burkitt Lymphoma in a 12-Year-Old Child. ( 27879544 )
2017
19
Age and geographic patterns of Plasmodium falciparum malaria infection in a representative sample of children living in Burkitt lymphoma-endemic areas of northern Uganda. ( 28320389 )
2017
20
Burkitt lymphoma as a lead point for jejunojejunal intussusception in a human immunodeficiency virus patient. ( 28523628 )
2017
21
Inhibition of monocarboxylate transporter 1 by AZD3965 as a novel therapeutic approach for the treatment of diffuse large B-cell lymphoma and Burkitt lymphoma. ( 28385782 )
2017
22
FAMLF is a target of miR-181b in Burkitt lymphoma. ( 28492808 )
2017
23
STAT3 mediates multidrug resistance of Burkitt lymphoma cells by promoting antioxidant feedback. ( 28483518 )
2017
24
Frequency and clinical implications of SOX11 expression in Burkitt lymphoma. ( 27869516 )
2016
25
Disseminated Renal Burkitt Lymphoma With Malignant Inferior Vena Caval Thrombosis in a Child. ( 26993348 )
2016
26
Burkitt lymphoma in a child with Bloom syndrome. ( 26774895 )
2016
27
Hematogones With Lambda Light Chain Restriction in a 4-Year-Old Boy With Burkitt Lymphoma: A Potential Diagnostic Pitfall. ( 27069035 )
2016
28
The use of anthracyclines in the treatment of endemic Burkitt lymphoma. ( 27891583 )
2016
29
Rare Case of Primary Gastric Burkitt Lymphoma in a Child. ( 27554215 )
2016
30
Ileo-Colic Burkitt Lymphoma in a Young Adult Female- A Case Report. ( 27190885 )
2016
31
Multiple Defects Impair the HLA Class II Antigen Presentation Capacity of Burkitt Lymphoma. ( 27747135 )
2016
32
Burkitt Lymphoma Preceded by Autoimmune Hemolytic Anemia due to Anti-D Antibody. ( 27523004 )
2016
33
18F-FDG PET/CT Imaging of Burkitt Lymphoma Presenting With Unusual Muscle Involvement. ( 27124681 )
2016
34
Differential IgM expression distinguishes two types of pediatric Burkitt lymphoma in mouse and human. ( 27566574 )
2016
35
Update on Burkitt Lymphoma. ( 27888884 )
2016
36
Age-related heterogeneity of Burkitt lymphoma. ( 27469517 )
2016
37
Primary Burkitt lymphoma of the thyroid gland: case report of an exceptional type of thyroid neoplasm and review of the literature. ( 27175103 )
2016
38
Factors influencing survival among Kenyan children diagnosed with endemic Burkitt lymphoma between 2003 and 2011: A historical cohort study. ( 27136063 )
2016
39
Outcomes for paediatric Burkitt lymphoma treated with anthracycline-based therapy in Malawi. ( 26914979 )
2016
40
Sporadic Burkitt Lymphoma Presenting as Intestinal Polyposis in a Child. ( 27941561 )
2016
41
Pediatric B-Cell Lymphoma With Lymphoblastic Morphology, TdT Expression, MYC Rearrangement, and Features Overlapping With Burkitt Lymphoma. ( 26785246 )
2016
42
An Extremely Rare Intersection: Neurolymphomatosis in a Patient with Burkitt Lymphoma Detected by 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. ( 27651745 )
2016
43
Sporadic Burkitt Lymphoma Presenting as Acute Pancreatitis, Concurrent Sinusitis, and Enlarged Adenoids. ( 27213067 )
2016
44
Clinicopathological prognostic factors of 24 patients with B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. ( 27095041 )
2016
45
Primary sporadic Burkitt lymphoma of the orbit, clinical characteristics, management, and outcomes: a case study. ( 26767843 )
2016
46
Burkitt Lymphoma Presented as Acute Lower Back Pain and Revealed by 18F-NaF PET/CT. ( 26825214 )
2016
47
Relapsed Burkitt Lymphoma Presenting as an Isolated Infiltrative Optic Neuropathy. ( 27928397 )
2016
48
Burkitt lymphoma express oncofetal Chondroitin Sulfate without being a reservoir for placental malaria sequestration. ( 27997697 )
2016
49
A Case Series of diffuse large B-cell lymphoma and burkitt lymphoma presenting with peritoneal lymphomatosis. ( 27756028 )
2016
50
The fortuitous diagnosis of Burkitt lymphoma in a patient with chronic myelomonocytic leukemia. ( 26800105 )
2016

Variations for Burkitt Lymphoma

ClinVar genetic disease variations for Burkitt Lymphoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 MYC NM_002467.4(MYC): c.214C> T (p.Pro72Ser) single nucleotide variant Pathogenic rs28933407 GRCh37 Chromosome 8, 128750677: 128750677
2 MYC NM_002467.4(MYC): c.302A> C (p.Asn101Thr) single nucleotide variant Pathogenic/Likely pathogenic rs121918683 GRCh37 Chromosome 8, 128750765: 128750765
3 MYC NM_002467.4(MYC): c.162G> C (p.Glu54Asp) single nucleotide variant Pathogenic rs121918684 GRCh37 Chromosome 8, 128750625: 128750625
4 MYC NM_002467.4(MYC): c.220C> G (p.Pro74Ala) single nucleotide variant Pathogenic rs121918685 GRCh37 Chromosome 8, 128750683: 128750683

Copy number variations for Burkitt Lymphoma from CNVD:

7 (show top 50) (show all 157)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13309 1 150547027 150552214 Copy number MCL1 Burkitt''s lymphoma
2 17456 1 142870000 177000000 Gain BCA2 Burkitt''s lymphoma
3 17457 1 142870000 177000000 Gain BCL9 Burkitt''s lymphoma
4 17458 1 142870000 177000000 Gain LHX4 Burkitt''s lymphoma
5 17459 1 142870000 177000000 Gain PIAS3 Burkitt''s lymphoma
6 20085 1 15300000 212100000 Insertion NOTCH2 Burkitt''s lymphoma
7 22188 1 166155454 171863618 Gain FASLG Burkitt''s lymphoma
8 25990 1 195253751 195672280 Gain PTPRC Burkitt''s lymphoma
9 26526 1 200970000 201360000 Gain LRRN5 Burkitt''s lymphoma
10 26527 1 200970000 201360000 Gain MDM4 Burkitt''s lymphoma
11 26528 1 200970000 201360000 Gain PIK3C2B Burkitt''s lymphoma
12 26529 1 200970000 201360000 Gain PLEKHA6 Burkitt''s lymphoma
13 26530 1 200970000 201360000 Gain PPP1R15B Burkitt''s lymphoma
14 29698 1 23457835 23714048 Loss E2F2 Burkitt''s lymphoma
15 30116 1 240240000 241350000 Gain ADSS Burkitt''s lymphoma
16 30117 1 240240000 241350000 Gain AKT3 Burkitt''s lymphoma
17 30118 1 240240000 241350000 Gain C1orf100 Burkitt''s lymphoma
18 30119 1 240240000 241350000 Gain C1orf101 Burkitt''s lymphoma
19 30120 1 240240000 241350000 Gain C1orf121 Burkitt''s lymphoma
20 30121 1 240240000 241350000 Gain FAM36A Burkitt''s lymphoma
21 30122 1 240240000 241350000 Gain HNRPU Burkitt''s lymphoma
22 30123 1 240240000 241350000 Gain LOC440742 Burkitt''s lymphoma
23 30124 1 240240000 241350000 Gain ZNF238 Burkitt''s lymphoma
24 42609 10 36983732 37133784 Loss Burkitt''s lymphoma
25 48364 11 1 32410000 Loss FANCF Burkitt''s lymphoma
26 48365 11 1 32410000 Loss PLEKHA7 Burkitt''s lymphoma
27 49723 11 110620000 110810000 Gain C11orf53 Burkitt''s lymphoma
28 49724 11 110620000 110810000 Gain POU2AF1 Burkitt''s lymphoma
29 50222 11 115828212 118580638 Gain Burkitt''s lymphoma
30 50968 11 120700000 134452384 Deletion Burkitt''s lymphoma
31 51055 11 122263650 134452384 Loss Burkitt''s lymphoma
32 51545 11 127825348 127931093 Gain ETS1 Burkitt''s lymphoma
33 64462 12 128465362 132449811 Gain Burkitt''s lymphoma
34 67044 12 35400000 132349534 Insertion Burkitt''s lymphoma
35 70408 12 61724591 82263925 Gain Burkitt''s lymphoma
36 74099 13 100500000 109100000 Insertion Burkitt''s lymphoma
37 74289 13 103640000 112610000 Loss ANKRD10 Burkitt''s lymphoma
38 74290 13 103640000 112610000 Loss ARHGEF7 Burkitt''s lymphoma
39 74291 13 103640000 112610000 Loss COL4A1 Burkitt''s lymphoma
40 74292 13 103640000 112610000 Loss COL4A2 Burkitt''s lymphoma
41 74293 13 103640000 112610000 Loss EFNB2 Burkitt''s lymphoma
42 74294 13 103640000 112610000 Loss ERCC5 Burkitt''s lymphoma
43 74295 13 103640000 112610000 Loss FGF14 Burkitt''s lymphoma
44 74296 13 103640000 112610000 Loss ING1 Burkitt''s lymphoma
45 74297 13 103640000 112610000 Loss IRS2 Burkitt''s lymphoma
46 74298 13 103640000 112610000 Loss LIG4 Burkitt''s lymphoma
47 74299 13 103640000 112610000 Loss PCCA Burkitt''s lymphoma
48 74300 13 103640000 112610000 Loss RAB20 Burkitt''s lymphoma
49 74301 13 103640000 112610000 Loss SLC10A2 Burkitt''s lymphoma
50 74302 13 103640000 112610000 Loss TNFSF13B Burkitt''s lymphoma

Expression for Burkitt Lymphoma

Search GEO for disease gene expression data for Burkitt Lymphoma.

Pathways for Burkitt Lymphoma

Pathways related to Burkitt Lymphoma according to GeneCards Suite gene sharing:

(show all 20)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.27 BAX CCND2 CCND3 CD40 CD40LG CXCL13
2
Show member pathways
12.67 AICDA CD40 CD40LG CXCL13 CXCR5 IFNA1
3 12.29 AICDA BCL6 CD40LG IFNA1 PAX5 SH2D1A
4
Show member pathways
12.25 BAX CCND2 CCND3 MYC
5
Show member pathways
12.21 BAX CCND2 CCND3 MYC
6 12.14 BAX CCND2 CCND3 CD40 MYBL1 MYC
7
Show member pathways
12.06 CCND2 CCND3 IFNA1 MYC
8 12.06 BCL6 CCND2 CD40 MYC PAX5
9 11.74 CR2 DNTT MS4A1
10 11.64 BAX CCND2 MYC
11 11.61 BAX BCL6 CCND2 CCND3 MYC
12
Show member pathways
11.54 CCND2 CCND3 MYC
13 11.47 AICDA BCL6 CD40LG MYBL1
14 11.34 BCL6 CD40 CD40LG CR2 CXCL13 CXCR5
15 11.33 CCND2 CCND3 MYC
16 11.24 AICDA CD40 CD40LG
17 11.2 CCND2 CCND3 MYC
18 11.09 CD40 CD40LG MYC
19 10.89 BCL6 CD40 CD40LG CR2 CXCR5 MS4A1
20 10.87 BAX CCND3

GO Terms for Burkitt Lymphoma

Cellular components related to Burkitt Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cyclin-dependent protein kinase holoenzyme complex GO:0000307 8.96 CCND2 CCND3
2 external side of plasma membrane GO:0009897 8.92 CD40 CD40LG CXCR5 MS4A1

Biological processes related to Burkitt Lymphoma according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.85 CD40 CD40LG CR2 CXCL13 CXCR5
2 regulation of cell proliferation GO:0042127 9.73 BCL6 CCND3 CD40 CXCL13
3 regulation of immune response GO:0050776 9.71 BCL6 CD40 CD40LG SH2D1A
4 lymph node development GO:0048535 9.52 CXCL13 CXCR5
5 isotype switching GO:0045190 9.51 AICDA CD40LG
6 hypothalamus development GO:0021854 9.49 BAX MYC
7 positive regulation of endothelial cell apoptotic process GO:2000353 9.48 CD40 CD40LG
8 humoral immune response GO:0006959 9.46 IFNA1 MS4A1 PAX5 SH2D1A
9 B cell activation GO:0042113 9.43 CD40 CXCR5 MS4A1
10 germinal center formation GO:0002467 9.37 BCL6 CXCL13
11 B cell differentiation GO:0030183 9.35 AICDA BCL6 CD40LG CR2 IFNA1
12 regulation of immunoglobulin secretion GO:0051023 9.32 CD40 CD40LG
13 B cell proliferation GO:0042100 9.02 CD40 CD40LG CR2 IFNA1 MS4A1

Molecular functions related to Burkitt Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding GO:0001077 8.92 MYBL1 MYC PAX5 SOX11

Sources for Burkitt Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....